Regeneron Was the Last Holdout. The White House Just Got Its Deal.

Pillar two: a free gene therapy. This one raised eyebrows. Otarmeni, a newly FDA-approved gene therapy for children with a rare form of genetic deafness, will be offered free to eligible U.S. patients. Gene therapies often carry seven-figure price tags, so "free" is a word you almost never hear in this space. It's a headline-grabbing concession, though the patient population is tiny.

Pillar three: a massive domestic investment. Regeneron committed $27 billion in American R&D and manufacturing by 2029, which the company says will double its U.S. biologic production capacity.

In return, Regeneron gets three years of tariff relief on drug imports and immunity from future pricing mandates. Think of it like a peace treaty: both sides gave something up, and both sides got something they wanted.

The Elephant in the Room: Dupixent

So what wasn't on the chopping block? That's where things get interesting.

Regeneron's crown jewel is Dupixent, the blockbuster anti-inflammatory drug it co-developed with Sanofi. This thing is a monster. It pulled in approximately €15.7 billion ($18.7 billion) in global sales in 2025, up 25% from the prior year at constant exchange rates. Q1 2026 sales came in at €4.2 billion ($4.6 billion), growing roughly 31% year-over-year at constant exchange rates. Analysts see it on a trajectory toward $20 billion in annual revenue.

The deal's emphasis on Medicaid pricing and newer products like Praluent and Otarmeni is notable partly for what it avoids. Dupixent's commercial pricing wasn't the centerpiece of negotiations, which likely made the deal more palatable for Regeneron's leadership (and its shareholders). When your biggest product is growing at 30%+ annually, you don't want Washington putting a ceiling on it.

Meanwhile, the company's other major franchise, Eylea (a retinal disease treatment), is already under pressure. Q1 2026 sales fell 28% to $1.1 billion as biosimilar competition looms in the second half of this year. Eylea was arguably less of a bargaining chip and more of a ticking clock.

The Bigger Picture: A New Playbook for Pharma Pricing

Zoom out, and the pattern across all 17 deals starts to look less like individual negotiations and more like an emerging framework. The template goes something like this:

1. Discounts on specific drugs sold through TrumpRx.gov
2. Most-favored-nation pricing for Medicaid and new products
3. Domestic manufacturing commitments (jobs, factories, investment)
4. Three-year tariff exemptions and protection from future mandates

It's a formula. And it's worth comparing to the other federal pricing program taking shape simultaneously.

The Inflation Reduction Act's Medicare negotiation program, which Congress passed in 2022, lets the government negotiate prices directly for high-cost drugs in Medicare. The first batch of negotiated prices took effect on January 1, 2026, covering 10 Part D drugs. CBO projects the program will save Medicare approximately $99 billion over ten years.

So now the pharmaceutical industry is navigating two parallel pricing regimes: one based on legislative authority (the IRA), the other on executive pressure and tariff leverage (the MFN deals). They pull in the same direction, but they use very different tools. The IRA is a statute. The MFN deals are, essentially, voluntary agreements backed by the implicit threat of tariffs.

That distinction matters. Statutes are hard to undo. Executive agreements can evaporate with the next administration.

Who Actually Benefits?

The White House is framing this as a win for patients, and for certain populations, it genuinely is. Medicaid recipients will see lower prices. Patients who use TrumpRx.gov can access specific drugs at steep discounts. Kids with rare genetic deafness get a free gene therapy.

But critics have pointed out the limits. These deals primarily target government programs. If you're a commercially insured American picking up a prescription at CVS, your out-of-pocket costs may not change much. The 80% market coverage number sounds comprehensive, but coverage doesn't always equal savings at the pharmacy counter.

There's also the question of what companies get in return. Three years of tariff immunity is a significant concession. So is protection from future pricing mandates. The companies essentially locked in a known cost (lower prices on select drugs) to avoid an unknown one (potential tariffs or harsher regulation). That's a trade most CFOs would take every time.

What Comes Next

With all 17 deals now signed, the White House's MFN initiative enters a new phase. The negotiating is done; now comes implementation. TrumpRx.gov needs to actually deliver drugs to patients at the promised prices. Companies need to follow through on their manufacturing pledges. And the administration needs to demonstrate measurable savings before the next election cycle.

For Regeneron specifically, 2026 is shaping up as a pivotal year beyond just this deal. Dupixent is expanding into new conditions like COPD and chronic spontaneous urticaria.

The pricing deal adds one more variable to an already complex equation. It constrains some revenue streams while offering regulatory breathing room on others. Whether that trade-off pays off depends on how aggressively the company can grow its newer products under the MFN framework.

One thing is clear: the days of American patients silently paying the highest drug prices on Earth are getting louder pushback. The mechanism is still being debated (legislation vs. executive deals vs. tariff threats), but the direction of travel isn't. Prices are coming down. The only question is how fast, how far, and who bears the cost.

Regeneron held out the longest. But even the last holdout eventually signs.

Why Pfizer Just Bet Its Cancer Brand on a Rookie Quarterback

Pfizer tapped NFL Draft prospect Fernando Mendoza as the face of its cancer screening campaign, and it's not just a feel-good play. Behind the football metaphors is a $43 billion oncology strategy that needs a bigger funnel.